Jon is Co-Founder of the Asia Microbiota Bank, a microbiome company headquartered in Hong Kong. Previously, Mr. Chang was a corporate development director for a US technology company where he was responsible for regional strategy and mergers and acquisitions. He was also a senior investment manager for a Chinese healthcare conglomerate, focusing on hospital and pharmaceutical investment projects. He lead numerous hospital system related investment and JV negotiations as well as pharmaceutical licensing deals. Mr. Chang is originally from California, and has spent close to a decade in Beijing and Hong Kong. He is fluent in Mandarin and English. He holds an MBA from Tsinghua-MIT business program.
Human microbiota transplantation (aka fecal transplantation) is being used for an increasing set of patient conditions as better clinical data emerges about the procedure. The Asia Microbiota Bank (AMB), the first commercial stool microbiota bank combined with Transplant Center in Asia, shares their story, how they identified healthy donors, conducted transplants, and analyzed the clinical and metagenomic data. AMB will share case studies on the clinical outcomes from patients with irritable bowel syndrome, intestinal bowel disease, chronic diarrhea, gut dysbiosis, ulcerative colitis, ALS and more. These cases are paving the way to discovering new bacterial strains not yet offered in an isolated form. Co-founder, Jon Chang, will share: